Open an account

Gossamer Bio

GOSS · NASDAQ

$9.58+$1.15 (+13.64%)TodayMarket closed ·
Prev close $8.43

About GOSS

Gossamer Bio, Inc. engages in discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. The company is headquartered in San Diego, California and currently employs 161 full-time employees. The company went IPO on 2019-02-08. Seralutinib, also known as GB002, is an investigational inhaled, small-molecule, platelet-derived growth factor receptor (PDGFR), colony-stimulating factor 1 receptor (CSF1R), and c-KIT inhibitor, being evaluated in a Phase III clinical trial for the treatment of PAH. Seralutinib is designed to target the mechanisms that underlie pulmonary hypertension and to be delivered to the site of disease, via dry powder inhaler. Seralutinib is being evaluated in a Phase III clinical trial for the treatment of pulmonary arterial hypertension (PAH). Inhaled seralutinib, which is designed to act on both isoforms of the PDGFR, α and β, as well as the CSF1R and c-KIT pathways.

Employees
161
Headquarters
San Diego, California
Listed
Feb 8, 2019
Sector
Health Care
Industry
Biotechnology
Website
gossamerbio.com

GOSS key statistics

Market cap
58.54M
Price-earnings ratio
0.00
Dividend yield
—
Average volume
291.35K
Volume
214.67K
Open price
$8.41
High today
$9.63
Low today
$8.29
52 Week high
$309.60
52 Week low
$8.31

Gossamer Bio (GOSS) at a glance

As of Oct 20, 2026, Gossamer Bio (GOSS) shares are priced at $9.58, giving the company a market cap of 58.54M and a price-to-earnings ratio of 0.00.

Today the stock has traded between $8.29 and $9.63. The current price is 15.6% above the day's low and 0.5% below its high.

Volume so far is 214.67K shares, below the average of 291.35K shares a day.

Over the past year Gossamer Bio has ranged from $8.31 to $309.60, and now sits 0% of the way up that range.

Gossamer Bio met or beat analyst EPS estimates in 5 of the last 8 quarters. In Q2 FY26 it reported $4.00 per share against an estimate of -$10.14.

The average analyst price target is $80.05, 735.6% above the current price, from 7 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

57%of 7 analyst ratings say Buy
  • Buy57.1%
  • Hold28.6%
  • Sell14.3%
Price target · 7 analystsAvg $80.05
Low
$22.62
Now
$9.58
High
$126.00

GOSS earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 5 of the last 8 quarters, by 36.9% on average.

  1. Q3 FY24: reported -$0.14 per share against an estimate of -$0.1508
  2. Q4 FY24: reported -$0.15 per share against an estimate of -$0.1734
  3. Q1 FY25: reported -$0.16 per share against an estimate of -$0.1913
  4. Q2 FY25: reported -$0.17 per share against an estimate of -$0.1847
  5. Q3 FY25: reported -$0.21 per share against an estimate of -$0.1956
  6. Q4 FY25: reported -$0.21 per share against an estimate of -$0.1996
  7. Q1 FY26: reported -$16.00 per share against an estimate of -$13.48
  8. Q2 FY26: reported $4.00 per share against an estimate of -$10.14

GOSS news

  • Press releaseBusiness Wire

    Gossamer Bio Submits New Drug Application to U.S. FDA for Seralutinib for the Treatment of Pulmonary Arterial Hypertension

  • Press releaseBusiness Wire

    Gossamer Bio Appoints Greg Ciongoli to Board of Directors

  • Press releaseBusiness Wire

    Gossamer Bio Announces Effectiveness of 1-for-80 Reverse Stock Split

  • Press releaseBusiness Wire

    Gossamer Bio Announces 1-for-80 Reverse Stock Split

  • Press releaseBusiness Wire

    Gossamer Bio to Present at Cantor Global Healthcare Conference

  • Akanksha Bakshi

    Gossamer Bio Slides as $250M Financing Hinges on FDA Milestones

  • 12 Health Care Stocks Moving In Friday's Pre-Market Session

  • Press releaseBusiness Wire

    Gossamer Bio Announces Up to $250 Million Structured Private Placement, Including $150 Million of Committed Capital, to Fund Seralutinib Through Potential FDA Approval

Similar companies

Companies in the same industry as Gossamer Bio

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.